Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C2H4O2 |
| Molecular Weight | 60.052 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O
InChI
InChIKey=QTBSBXVTEAMEQO-UHFFFAOYSA-N
InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)
| Molecular Formula | C2H4O2 |
| Molecular Weight | 60.052 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| StereoComments | testing |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08eCurator's Comment: description was created based on several sources, including
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08e
Curator's Comment: description was created based on several sources, including
Acetic acid (a component of vinagre) is used in medicine for the treatment of otitis externa caused by bacterial infections. The solution containing acetic acid was approved by FDA.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14668053https://www.ncbi.nlm.nih.gov/pubmed/2117062
Curator's Comment: Acetic acid was shown to cross the blood brain barrier in rats.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: cyanide ions |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | CYANOKIT Approved UseCyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. (1.1) If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. (1.2) The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (1.2) 1.1 Indication Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. 1.2 Identifying Patients with Cyanide Poisoning Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside. The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. Table 1 Common Signs and Symptoms of Cyanide Poisoning Symptoms Signs Headache Altered Mental Status (e.g., confusion,disorientation) Confusion Seizures or Coma Dyspnea Mydriasis Chest tightness Tachypnea / Hyperpnea (early) Nausea Bradypnea / Apnea (late) Hypertension (early) / Hypotension (late) Cardiovascular collapse Vomiting Plasma lactate concentration ≥ 8 mmol/L In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Smoke Inhalation Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following: Exposure to fire or smoke in an enclosed area Presence of soot around the mouth, nose or oropharynx Altered mental status Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration ≥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration. 1.3 Use with Other Cyanide Antidotes Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line. [see Dosage and Administration (2.3) Launch Date2006 |
|||
| Curative | VOSOL Approved UseFor the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial. Launch Date1960 |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4511.6 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
26.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
20 mg 1 times / day multiple, intramuscular Dose: 20 mg, 1 times / day Route: intramuscular Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 13 years |
|
20 g single, intravenous Highest studied dose Dose: 20 g Route: intravenous Route: single Dose: 20 g Sources: |
unhealthy, 26.9 years Health Status: unhealthy Age Group: 26.9 years Sex: M Sources: |
|
5 g single, intravenous Overdose |
unhealthy, 3 years |
|
5 g single, intravenous |
unhealthy, 62 years |
|
2000 ug 2 times / day multiple, oral Dose: 2000 ug, 2 times / day Route: oral Route: multiple Dose: 2000 ug, 2 times / day Sources: |
unhealthy, adult |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Direct exposure to ammonia and hyperammonemia increase the extracellular accumulation and degradation of astroglia-derived glutathione in the rat prefrontal cortex. | 2010-09 |
|
| Effects of ammonia and allopurinol on rat hippocampal NMDA receptors. | 2010-03 |
|
| AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis. | 2010-01-22 |
|
| Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylates. | 2009-04-01 |
|
| Effects of acute ammonia toxicity on nitric oxide (NO), citrulline-NO cycle enzymes, arginase and related metabolites in different regions of rat brain. | 2005-10 |
|
| Utilization of geraniol is dependent on molybdenum in Pseudomonas aeruginosa: evidence for different metabolic routes for oxidation of geraniol and citronellol. | 2005-07 |
|
| [Antioxidant enzymes of the rat liver, brain, heart and erythrocytes in ammonia intoxication]. | 2005-06-11 |
|
| Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD metabolism in nuclei of rat brain cells. | 2004-06 |
|
| Sources of oxygen radicals in brain in acute ammonia intoxication in vivo. | 2003-08-15 |
|
| Cobalamin transport proteins and their cell-surface receptors. | 2003-06-13 |
|
| Ammonia-induced heme oxygenase-1 expression in cultured rat astrocytes and rat brain in vivo. | 2002-12 |
|
| Production of ethanol and xylitol from corn cobs by yeasts. | 2001-03 |
|
| Evaluation of a novel vitamin E coated cellulosic membrane hollow fiber dialyzer. | 2001-02-24 |
|
| Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring. | 2001-02 |
|
| Exploring infection of wheat and carbohydrate metabolism in Mycosphaerella graminicola transformants with differentially regulated green fluorescent protein expression. | 2001-02 |
|
| Di-tert-butyl phosphate complexes of cobalt(II) and zinc(II) as precursors for ceramic M(PO3)2 and M2P2O7 materials: synthesis, spectral characterization, structural studies, and role of auxiliary ligands. | 2001-01-29 |
|
| Modelling the influence of pH and organic acid types on thermal inactivation of Bacillus cereus spores. | 2001-01-22 |
|
| Identification of lactic acid bacteria constituting the predominating microflora in an acid-fermented condiment (tempoyak) popular in Malaysia. | 2001-01-22 |
|
| Control of electrochemical reactions at the capillary electrophoresis outlet/electrospray emitter electrode under CE/ESI-MS through the application of redox buffers. | 2001-01-15 |
|
| [DOTA-bis(amide)]lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers. | 2001-01-05 |
|
| Optimised determination of clobazam in human plasma with extraction and high-performance liquid chromatography analysis. | 2001-01-05 |
|
| [Acetyl starch as volume substitute, a possible alternative to HES]. | 2001-01-05 |
|
| Clostridium hungatei sp. nov., a mesophilic, N2-fixing cellulolytic bacterium isolated from soil. | 2001-01 |
|
| Long-term stability characterization of a controlled release gastrointestinal therapeutic system coated with a cellulose acetate pseudolatex. | 2001-01 |
|
| A survey of lipolytic and glycolytic end-products in commercial Cheddar enzyme-modified cheese. | 2001-01 |
|
| Cation-exchange purification of mutagenized bovine beta-casein expressed in transgenic mouse milk: its putative Asn68-linked glycan is heterogeneous. | 2001-01 |
|
| In vitro mixed ruminal microorganism fermentation of whole cottonseed coated with gelatinized corn starch and urea. | 2001-01 |
|
| Teprenone promotes the healing of acetic acid-induced chronic gastric ulcers in rats by inhibiting neutrophil infiltration and lipid peroxidation in ulcerated gastric tissues. | 2001-01 |
|
| Effect of ruminal vs postruminal administration of degradable protein on utilization of low-quality forage by beef steers. | 2001-01 |
|
| Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography. | 2001-01 |
|
| Measurement of myocardial blood flow with PET using 1-11C-acetate. | 2001-01 |
|
| Subcellular localization of Rab17 by cryo-immunogold electron microscopy in epithelial cells grown on polycarbonate filters. | 2001 |
|
| Evaluation of copper availability to plants in copper-contaminated vineyard soils. | 2001 |
|
| Conversion of 4-hydroxyacetophenone into 4-phenyl acetate by a flavin adenine dinucleotide-containing Baeyer-Villiger-type monooxygenase. | 2000-12 |
|
| Characterization of two novel propachlor degradation pathways in two species of soil bacteria. | 1999-02 |
|
| Carbon-arsenic bond cleavage by a newly isolated gram-negative bacterium, strain ASV2. | 1995-03 |
|
| Cloning and sequencing of the gene which encodes the highly inducible acetamidase of Mycobacterium smegmatis. | 1993-03 |
|
| Location and sequence of the todF gene encoding 2-hydroxy-6-oxohepta-2,4-dienoate hydrolase in Pseudomonas putida F1. | 1991-07-31 |
|
| Purification and characterization of aryl acylamidase from Nocardia globerula. | 1991-07-01 |
|
| Enzymes of vitamin B6 degradation. Purification and properties of 5-pyridoxic-acid oxygenase from Arthrobacter sp. | 1986-11-15 |
|
| Bacterial organomercurial lyase: overproduction, isolation, and characterization. | 1986-11-04 |
|
| Enzymes of vitamin B6 degradation. Purification and properties of two N-acetylamidohydrolases. | 1985-02-25 |
|
| Disruption of the blood-brain barrier in hyperammonemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine. | 1985 |
|
| Prevention of methionine and ammonia-induced coma by intravenous infusion of a branched chain amino acid solution to rats with liver injury. | 1984-10 |
|
| Modification of drug action by hyperammonemia. | 1984-04 |
|
| Metabolism of resorcinylic compounds by bacteria. Purification and properties of acetylpyruvate hydrolase from Pseudomonas putida 01. | 1975-05-25 |
|
| Microbiological degradation of diazepam. | 1975 |
|
| The degradation of paracetamol (4-hydroxyacetanilide) and other substituted acetanilides by a Penicillium species. | 1975 |
|
| Purification and characterization of the nocardial acetylesterase involved in 2-butanone degradation. | 1974-12 |
|
| The utilization of acetate for synthesis in Escherichia coli. | 1954-03 |
Patents
Sample Use Guides
Cyanokit (hydroxocobalamin for injection): one 5 g vial is a complete starting dose
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6692038
Curator's Comment: Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. In a series of experiments, were compared the uptake and internalization of OH-Cbl and CN-Cbl bound to transcobalamin II (TCII) by a human cell model, the HeLa cell. TCII-OH-Cbl was: (1) taken up in larger amounts per unit time, (2) the greater uptake was not a consequence of more effective attachment to receptors of TCII-Cbl nor to a more rapid regeneration of receptors, (3) the difference was expressed during the phase of internalization of TCII-Cbl, (4) with CN-Cbl, the stages of binding to receptors plus internalization were more readily reversed, and (5) larger amounts of OH-Cbl were internalized and converted to active coenzyme forms of Cbl.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:47:13 GMT 2025
by
admin
on
Mon Mar 31 17:47:13 GMT 2025
|
| Record UNII |
Q40Q9N063P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 447
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1025
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1081
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 323
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1247
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 724
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
28
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-ATC |
S02AA10
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
JECFA EVALUATION |
ACETIC ACID
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 879
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
NCI_THESAURUS |
C254
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
FDA ORPHAN DRUG |
706219
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-ATC |
G01AD02
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-VATC |
QG01AD02
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1144
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
DSLD |
396 (Number of products:5)
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1096
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 951
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1236
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
CFR |
21 CFR 184.1005
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 908
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 728
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 993
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-260
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1035
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 887
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1132
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-VATC |
QS02AA10
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1089
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 880
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 561
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 140
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
JECFA EVALUATION |
INS-260
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1082
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 801
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1094
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
15366
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
Acetic acid (medical use)
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
406306
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
ACETIC ACID
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
168
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID5024394
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
200-580-7
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
1005706
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
100000088999
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
4211
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
ACETIC ACID
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | Description: Clear, colourless liquids. At a temperature below 15 ?C Glacial acetic acid may occur as a translucent, crystalline mass; odour, characteristic and pungent. Miscibility: Miscible with water, ethanol (~750 g/l) TS, and glycerol R. Category: Acidifying agent. Storage: Acetic acid should be kept in a tightly closed container. Additional information: Glacial acetic acid is flammable and should be handled with care. Congealing point, about 15 ?C. | ||
|
D019342
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
SUB11689MIG
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
CHEMBL539
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
3
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
176
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
127175
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
64-19-7
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
C61623
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
112209
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
m1324
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | Merck Index | ||
|
39
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
132953
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
463-83-2
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
ALTERNATIVE | |||
|
Q40Q9N063P
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
DB03166
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
115870
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
SUB12711MIG
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
Q40Q9N063P
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
111201
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> METABOLITE |
|
||
|
|
PARENT -> METABOLITE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
|
PARENT -> IMPURITY |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|